Reactions to learning a “not elevated” amyloid PET result in a preclinical Alzheimer’s disease trial

BackgroundThe experiences of biomarker-ineligible cognitively normal persons can inform trial conduct and the translation of preclinical Alzheimer’s disease (AD) into clinical practice.MethodsWe interviewed 33 persons whose “not elevated” brain amyloid imaging biomarker result made them ineligible for a preclinical AD trial.ResultsMost participants (n = 17) reported being informed that they did not demonstrate adequately elevated amyloid to qualify, whereas some (n = 14) reported being told they had no amyloid or plaques. Relief (n = 17) and disappointment related to not being able to participate (n = 12) were the most common reactions to results. Nearly all participants would have made healthy lifestyle changes if they had received an “elevated” result, would have another scan, and would participate in another AD prevention trial.ConclusionsAlthough some participants may misconstrue results, disclosure of a “not elevated” amyloid result in the research setting causes little behavior change; willingness to participate in AD research remains.

[1]  W. Jagust,et al.  Subthreshold Amyloid Predicts Tau Deposition in Aging , 2018, The Journal of Neuroscience.

[2]  M. Horowitz,et al.  Impact of Event Scale: A Measure of Subjective Stress , 1979, Psychosomatic medicine.

[3]  W. Klunk,et al.  Predicting positivity for a new era of Alzheimer disease prevention trials , 2012, Neurology.

[4]  W. Jagust,et al.  Memory decline accompanies subthreshold amyloid accumulation , 2018, Neurology.

[5]  W. Klunk,et al.  Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment. , 2016, Journal of Alzheimer's disease : JAD.

[6]  W. Klunk,et al.  Disclosure of amyloid imaging results to research participants: Has the time come? , 2013, Alzheimer's & Dementia.

[7]  M. Weiner,et al.  Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons , 2017, JAMA.

[8]  J. Karlawish,et al.  Study partners should be required in preclinical Alzheimer’s disease trials , 2017, Alzheimer's Research & Therapy.

[9]  E. Vidoni,et al.  Safety of disclosing amyloid status in cognitively normal older adults , 2017, Alzheimer's & Dementia.

[10]  Grahame Smith,et al.  The way forward , 2018, Reaching Net Zero.

[11]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[12]  J. Karlawish,et al.  The A4 Study: Stopping AD Before Symptoms Begin? , 2014, Science Translational Medicine.

[13]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[14]  C. Brayne,et al.  Psychological, behavioral and social effects of disclosing Alzheimer’s disease biomarkers to research participants: a systematic review , 2016, Alzheimer's Research & Therapy.

[15]  J. Karlawish,et al.  Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults , 2018, JAMA neurology.

[16]  J. Karlawish,et al.  Study partners: essential collaborators in discovering treatments for Alzheimer’s disease , 2018, Alzheimer's Research & Therapy.

[17]  Craig Ritchie,et al.  Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit , 2016, Alzheimer's & Dementia.

[18]  R. Vandenberghe,et al.  From information to follow-up: Ethical recommendations to facilitate the disclosure of amyloid PET scan results in a research setting , 2018, Alzheimer's & dementia.

[19]  E. Teng,et al.  Patient and caregiver reactions to clinical amyloid imaging , 2017, Alzheimer's & Dementia.

[20]  W. M. van der Flier,et al.  Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review , 2018, Alzheimer's Research & Therapy.

[21]  J. Karlawish,et al.  Confidentiality in preclinical Alzheimer disease studies , 2014, Neurology.

[22]  J. Roberts,et al.  Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues. , 2013, Neurodegenerative disease management.

[23]  Pedro Rosa-Neto,et al.  Use of amyloid PET across the spectrum of Alzheimer’s disease: clinical utility and associated ethical issues , 2014, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[24]  P. Snyder,et al.  Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability , 2016, Alzheimer's & Dementia.

[25]  M. Leok.  The use of , 1996 .

[26]  Story C. Landis,et al.  Preventing Cognitive Decline and Dementia: A Way Forward , 2017 .

[27]  J. Burns,et al.  Should we disclose amyloid imaging results to cognitively normal individuals? , 2013, Neurodegenerative disease management.

[28]  Keith A. Johnson,et al.  Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants , 2014, Alzheimer's Research & Therapy.

[29]  J. Karlawish.  Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease , 2011, Neurology.

[30]  R. Beard,et al.  Making sense of nonsense: experiences of mild cognitive impairment. , 2013, Sociology of health & illness.

[31]  K. Yaffe,et al.  The projected effect of risk factor reduction on Alzheimer's disease prevalence , 2011, The Lancet Neurology.

[32]  Irena Stijacic Cenzer,et al.  Desire for predictive testing for Alzheimer’s disease and impact on advance care planning: a cross-sectional study , 2016, Alzheimer's Research & Therapy.